drug · small molecule
nemtabrutinib
Phase 2updated 6mo agoby $MRK Merck & Co., Inc.🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
indications
indications
DLBCL
all catalysts(0)
nothing on the calendar yet
Trials studying nemtabrutinib
- phase3A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- phase2Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- phase3A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- phase1A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
- phase2Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- phase2A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
- phase2Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- phase1A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
News(4)
- Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsMerck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.biospace · 2h ago
- STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and moreThe Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senatestat · 2h ago
- Merck ends the sorry saga of BTK inhibitor it got from ArQuleMerck has ended development of a BTK inhibitor that was the main reason it bought ArQule for $2.7 billion in 2019. Nemtabrutinib, or MK-1026, was being investigated in a slew of trials in blood can…endpoints · 5h ago
- Merck axes $2.7B BTK inhibitor program after seeing phase 3 dataMerck & Co. has stopped a trio of phase 3 blood cancer trials after one study suggested the benefits of the BTK inhibitor may fail to outweigh the risks, bringing the curtain down on a program stem…fiercebiotech · 14h ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that